• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vac

tetano

Editor, Senior Moderator
J Control Release. 2019 Oct 31. pii: S0168-3659(19)30606-6. doi: 10.1016/j.jconrel.2019.10.042. [Epub ahead of print] [h=1]Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine.[/h]
Lodaya RN[SUP]1[/SUP], Kanitkar AP[SUP]2[/SUP], Friedrich K[SUP]2[/SUP], Henson D[SUP]2[/SUP], Yamagata R[SUP]2[/SUP], Nuti S[SUP]2[/SUP], Mallet CP[SUP]2[/SUP], Bertholet S[SUP]2[/SUP], Amiji MA[SUP]3[/SUP], O'Hagan DT[SUP]2[/SUP].
[h=3]Author information[/h] 1 Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA, 02115, USA. Electronic address: rushit.n.lodaya@gsk.com. 2 GSK, Slaoui Centre for Vaccines Research, Rockville, MD, 20850, USA. 3 Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA, 02115, USA.

[h=3]Abstract[/h] α-Tocopherol has been used as an immune supplement in humans, as an emulsion adjuvant component in several veterinary vaccines as well as an immunomodulatory component of AS03, an emulsion adjuvant that was used in an H1N1 pandemic vaccine (Pandemrix). AS03 is manufactured using microfluidization and high-pressure homogenization. Such high energy and complex manufacturing processes make it difficult and expensive to produce emulsion adjuvants on a large scale, especially in developing countries. In this study we have explored simpler, comparatively inexpensive methods, to formulate emulsion adjuvants containing α-tocopherol, that have the potential to be made in any well-established scale-up facility. This might facilitate producing and stock-piling adjuvant doses and therefore aide in pandemic preparedness. We used design of experiment as a tool to explore incorporating α-tocopherol into self-emulsified systems containing squalene oil and polysorbate 80. We created novel self-emulsified adjuvant systems (SE-AS) and evaluated their potency in vivo in BALB/c mice with inactivated quadrivalent influenza vaccine (QIV) and tested the cellular and humoral immune responses against the four vaccine strains.
Copyright ? 2019. Published by Elsevier B.V.


[h=4]KEYWORDS:[/h] Inactivated Quadrivalent Influenza Vaccine (QIV); Self-Emulsified Adjuvant Systems (SE-AS); Self-emulsification; Squalene; Vaccine Adjuvants; α-tocopherol

PMID: 31678654 DOI: 10.1016/j.jconrel.2019.10.042
 
Back
Top Bottom